TABLE 2.

Inhibition of peak transient and resurgent currents by sodium channel inhibitors

The peak transient current was measured at a test potential of +20 mV obtained from an I/V recording. The relative resurgent current amplitudes were calculated by dividing the peak resurgent current by the peak transient current and are represented as a percentage of the peak transient current.

	Ipeak	INaR	n
	nA	% Ipeak
WT
Control	−2.84 ± 0.36	4.9 ± 0.4	5
CBZ 200 μM	−2.14 ± 0.22*	3.8 ± 0.2*
Control	−5.45 ± 2.48	4.1 ± 0.7	6
RZ 30 μM	−3.77 ± 1.81	2.2 ± 0.2*
Control	−2.63 ± 0.57	5.3 ± 1.0	4
RZ 3 μM	−2.76 ± 0.59	5.4 ± 1.2
Control	−4.01 ± 0.73	4.6 ± 0.9	6
AEA 5 μM	−3.89 ± 0.75	2.1 ± 0.3*
Control	−7.02 ± 2.17	3.7 ± 0.07	5
AEA 500 nM	−8.22 ± 2.9	4.3 ± 0.6*
T1464I
Control	−1.84 ± 0.36	14.9 ± 1.1	6
CBZ 200 μM	−1.55 ± 0.30*	11.1 ± 0.8*
Control	−2.24 ± 0.6	15.1 ± 1.9	5
RZ 30 μM	−1.59 ± 0.47	9.0 ± 0.6*
Control	−2.02 ± 0.59	17.4 ± 2.7	4
RZ 3 μM	−2.21 ± 0.64	17.9 ± 3.1
Control	−1.26 ± 0.17	18.6 ± 0.9	5
AEA 5 μM	−1.30 ± 0.18	7.0 ± 1.2*
Control	−1.35 ± 0.5	19.0 ± 2.3	5
AEA 500 nM	−1.42 ± 0.53*	18.7 ± 2.1
M1627K
Control	−1.04 ± 0.21	15.4 ± 0.6	6
CBZ 200 μM	−0.84 ± 0.17*	13.6 ± 1.0*
Control	−0.74 ± 0.17	13.5 ± 0.5	6
RZ 30 μM	−0.52 ± 0.13*	9.7 ± 0.8*
Control	−1.16 ± 0.3	12.2 ± 0.8	5
RZ 3 μM	−1.16 ± 0.32	12.3 ± 0.7
Control	−0.95 ± 0.23	12.2 ± 1.0	5
AEA 5 μM	−0.91 ± 0.23*	5.6 ± 0.8*
Control	−0.94 ± 0.16	14.2 ± 1.5	4
AEA 500 nM	−0.92 ± 0.14	14.7 ± 0.9

I_NaR, resurgent current; CBZ, carbamazepine; RZ, riluzole; AEA, anandamide.

^* P < 0.05 from control by paired Student's t test.